Quick Answer
AGIOS PHARMACEUTICALS, INC. reported Research And Development Expense of $339.54 million for the year ending 2025.
- AGIOS PHARMACEUTICALS, INC. showed an increase of +12.7% in Research And Development Expense from 2024 to 2025.
- This data is from AGIOS PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2012: $10.46 million | Q3 2012: $9.80 million | Q1 2013: $11.46 million | Q2 2013: $12.96 million | Q3 2013: $14.80 million | Q1 2014: $17.41 million | Q2 2014: $22.58 million | Q3 2014: $25.53 million | Q1 2015: $32.44 million | Q2 2015: $36.42 million | Q3 2015: $36.03 million | Q1 2016: $44.04 million | Q2 2016: $50.80 million | Q3 2016: $60.64 million | Q1 2017: $62.73 million | Q2 2017: $79.82 million | Q3 2017: $72.92 million | Q1 2018: $78.22 million | Q2 2018: $86.73 million | Q3 2018: $82.56 million | Q1 2019: $95.59 million | Q2 2019: $107.39 million | Q3 2019: $101.67 million | Q1 2020: $55.36 million | Q2 2020: $54.09 million | Q3 2020: $51.94 million | Q1 2021: $57.67 million | Q2 2021: $62.01 million | Q3 2021: $64.00 million | Q1 2022: $70.12 million | Q2 2022: $74.52 million | Q3 2022: $64.97 million | Q1 2023: $67.30 million | Q2 2023: $68.90 million | Q3 2023: $81.84 million | Q1 2024: $68.62 million | Q2 2024: $77.40 million | Q3 2024: $72.46 million | Q1 2025: $72.74 million | Q2 2025: $91.94 million | Q3 2025: $86.80 million.
- Over the full 15 years of available data (2011 to 2025), AGIOS PHARMACEUTICALS, INC.'s Research And Development Expense has grown by 986.4%.
- Historical annual values: Fiscal year 2025: $339.54 million | Fiscal year 2024: $301.29 million | Fiscal year 2023: $295.53 million | Fiscal year 2022: $279.91 million | Fiscal year 2021: $256.97 million | Fiscal year 2020: $220.81 million | Fiscal year 2019: $214.26 million | Fiscal year 2018: $341.32 million | Fiscal year 2017: $292.68 million | Fiscal year 2016: $220.16 million | Fiscal year 2015: $141.83 million | Fiscal year 2014: $100.37 million | Fiscal year 2013: $54.50 million | Fiscal year 2012: $41.04 million | Fiscal year 2011: $31.25 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: